Before you sign up anywhere, ask five things: who prescribes, how you are monitored, the full monthly cost including refills, whether the medication is FDA-approved or compounded, and what the plan is when you stop. A search for weight loss near me returns storefront clinics, telehealth apps, and physician offices side by side, and most of them look identical on the homepage. The right questions expose the difference in about ten minutes.
Who is actually prescribing, and can you reach them?
This is the question that sorts real clinics from subscription funnels. Some services connect you to a licensed clinician who reviews your history, adjusts your dose, and answers questions when a side effect shows up. Others hand you an intake form, an automatic approval, and a monthly charge, with no reachable prescriber behind it. Both can look the same in an ad.
Ask directly: is there a licensed physician, nurse practitioner, or physician assistant responsible for my care, and how do I contact them between visits? GLP-1 medications carry warnings that matter, including thyroid C-cell tumor signals and pancreatitis risk noted in the Wegovy prescribing information. Dose changes and nausea management are not one-time events. You want a person, not a chatbot, on the other end.
How will progress and safety be monitored?
A weight-loss plan is not a vending machine. The 2025 clinical practice guideline update on pharmacotherapy for obesity frames these drugs as long-term treatment that should be paired with follow-up, not a single prescription. Ask how often the clinic checks in, whether it tracks weight and relevant labs, and what triggers a dose adjustment or a stop.
This is also where the in-person versus telehealth choice becomes concrete. A local office makes it simple to record weight, blood pressure, and bloodwork on site. Telehealth removes travel and usually costs less, but a good telehealth clinic still asks for labs and vitals rather than skipping them. The 2025 guideline on defining and diagnosing clinical obesity leans on objective measures beyond a single number on a form, which is worth remembering if a clinic approves you on almost no information.
What does the total monthly cost actually come to?
Headline prices are designed to look small. The honest figure is the medication plus visit fees plus any membership or lab charges, all in one number, and then that same number at a higher maintenance dose. Ask what changes when the dose goes up, because for several programs it does.
| Cost element | Question to ask | Common surprise |
|---|---|---|
| Medication | Brand or compounded, and price per month at target dose | Price rises with dose |
| Visit or consult fee | Charged per visit, monthly, or bundled | Separate from the drug price |
| Membership | Is there a recurring platform fee | Auto-renews independently |
| Labs | Included, extra, or your responsibility | Billed through a third party |
Is the medication FDA-approved or compounded?
You have a right to a plain answer here. Brand semaglutide and tirzepatide products are FDA-approved and backed by published trials. Compounded versions are prepared by a compounding pharmacy and are not FDA-approved products; they may contain the same active molecule but have not gone through the approval process that generated the brand evidence. That is a real distinction, not marketing language.
Neither route is automatically wrong. Compounded medication can offer a predictable cash price, and it should still be prescribed and supervised by a licensed clinician rather than sold like a supplement. If you are weighing a nearby office against a supervised telehealth practice, it helps to find a local provider and compare its pricing and prescriber access against national services like Ro, Hims and Hers, Henry Meds, or LillyDirect before committing. Ask each one the same question and see who answers cleanly.
What evidence supports the plan they are offering?
A clinic worth your money can explain what to expect from the specific drug it prescribes. The STEP 3 trial paired semaglutide with intensive behavioral therapy and reported roughly 16 percent mean weight loss at 68 weeks, a reminder that the medication works alongside habit change rather than replacing it. STEP 8 compared weekly semaglutide against daily liraglutide and found semaglutide produced larger reductions, which matters if a clinic is steering you toward an older agent for reasons it cannot explain.
You do not need a clinic to quote trial numbers to you. You do need it to have a coherent reason for its choices. The AGA guideline on pharmacological interventions for adults with obesity and the 2025 pharmacotherapy update both describe how agents are selected based on the individual, including coexisting conditions. If someone also has metabolic dysfunction-associated steatotic liver disease, the EASL-EASD-EASO guidelines are relevant to that conversation. A clinic that treats everyone identically is not really assessing anyone.
What is the plan when you stop?
This is the question clinics most want to avoid, and the one you should press hardest. Weight regain after stopping is well documented. In the STEP 1 trial extension, participants regained about two thirds of their lost weight in the year after semaglutide was withdrawn, and the STEP 4 trial showed that continued treatment maintained loss while switching to placebo led to regain. That is a property of the treatment, not a personal failure.
So ask what happens at month twelve. Does the clinic plan for maintenance dosing, taper conversations, and continued support, or does its business quietly depend on you regaining weight and coming back? An honest answer to that question tells you more than any homepage promise.
Key takeaways
- Confirm a reachable licensed prescriber before anything else; a form-only funnel is not clinical care.
- Add every fee into one monthly total, then ask what it becomes at the maintenance dose.
- Get a plain answer on whether the medication is FDA-approved or compounded.
- Weight regain after stopping is expected, so a serious clinic plans for maintenance up front.
See also: Thymulin vs. the Approved Stuff: A Former Gym Owner’s Take on Who’s Selling You What
Frequently asked questions
What is the single most useful question to ask first?
Ask who actually prescribes and whether you can reach a licensed clinician when something changes. A clinic that routes everything through a form with no reachable prescriber is selling a subscription, not care.
Is a local in-person clinic better than telehealth?
Neither is better by default. In-person visits make weight, labs, and vitals easy to track, while telehealth removes travel and often costs less. What matters is whether the clinic monitors you and adjusts the plan either way.
How do I compare prices honestly?
Add the medication, the visit fees, and any membership or lab charges into one monthly total, then ask how that number changes at higher doses. A low headline price often hides charges that appear once you are enrolled.
Are compounded GLP-1 medications the same as the brand?
No. Compounded semaglutide or tirzepatide is prepared by a compounding pharmacy and is not an FDA-approved product. It may use the same active molecule but has not gone through the approval process behind the brand trial evidence.
What should the clinic tell me about stopping the medication?
That weight regain after stopping is common and documented. A trial extension showed participants regained about two thirds of lost weight in the year after semaglutide was withdrawn. A serious clinic plans for maintenance rather than avoiding the subject.
